Due to poor air quality related to fires in California, the Academy’s San Francisco offices will be closed Friday, Nov. 16. Member support staff will not be available by phone and responses to emails may be delayed.

  • Bausch & Lomb

    Bausch & Lomb has initiated two phase 3 clinical studies of latanoprostene bunod to reduce IOP in patients with glaucoma or ocular hypertension. Licensed by Nicox S.A., the drug candidate is a nitric oxide-donating prostaglandin F2 alpha analog.

    Two separate randomized, multi-center, double-masked, parallel-group clinical studies, APOLLO and LUNAR, will compare the efficacy and safety of once-daily latanoprostene bunod with twice-daily timolol maleate 0.5 percent. The studies will include a combined total of approximately 800 patients. Their primary endpoint is reduction in mean IOP during three months of treatment.

    Bausch & Lomb's decision to proceed with this program followed positive phase 2 results showing latanoprostene bunod consistently lowered IOP in a dose-dependent manner. All four doses tested in the trial showed greater IOP reduction compared with Xalatan 0.005 percent, with the differences for two of the four doses reaching more than 1 mmHg (P<0.01).